Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.46439/nephrology.3.11
An update on proliferative glomerulonephritis with monoclonal immunoglobulin deposits in pediatric patients
Wesley Hiser, MD1, Guolan Xing2, Xin Jin Zhou1,*
- 1Renal Path Diagnostics, Pathologists BioMedical Laboratories/PathGroup, Dallas, Texas, USA
- 2Department of Nephrology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China 450052
Corresponding Author
Xin Jin Zhou, jzhou@pbmlabs.com
Received Date: October 05, 2021
Accepted Date: March 04, 2022
Hiser W, Xing G, Zhou XJ. An update on proliferative glomerulonephritis with monoclonal immunoglobulin deposits in pediatric patients. J Exp Nephrol. 2022;3(1):1-4.
Copyright: © 2022 Hiser W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
An update on proliferative glomerulonephritis with monoclonal immunoglobulin deposits in pediatric patients
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) was first described by Nasr et al. in 2004 with a subsequent study composed of a larger patient cohort a few years later [1,2]. Although more commonly occurring in older adults, PGNMID has since been reported in a wide range of age groups including children [3-5]. PGNMID is categorized as a monoclonal gammopathy of renal significance (MGRS), and is additionally included in the recently expanded concept of monoclonal gammopathy of clinical significance (MGCS), which encompasses disorders of any organ system related to underlying plasma cell or B-cell clones [6]; however, most patients with PGNMID do not show evidence of a circulating monoclonal protein or clonal plasma cell proliferation, and monoclonal gammopathy has not been reported in any pediatric patients with the disease. Herein we briefly discuss the clinical and histopathologic features of PGNMID, as well as advances in our understanding of the pathogenesis and clinical course of the disease.
Increased incidence of severe burns in pediatric patients during the COVID -19 pandemic
During the COVID-19 pandemic, an increase in the incidence of burns in the pediatric population was observed worldwide, in our institution an increase was observed in the same way in the year 2020 and after this in the year 2021, when pandemic restrictions were continued.